AI Article Synopsis
Article Abstract
Topical sirolimus, or rapamycin, is known to inhibit tumorigenesis in tuberous sclerosis. We report two cases of successful treatment of children with facial angiofibromata and summarize the encouraging evidence of the effectiveness of this therapy in the literature.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pde.12551 | DOI Listing |
Publication Analysis
Top Keywords
facial angiofibromata
8
successful topical
4
topical rapamycin
4
rapamycin treatment
4
treatment facial
4
angiofibromata children
4
children topical
4
topical sirolimus
4
sirolimus rapamycin
4
rapamycin inhibit
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!